A chronic inflammatory bowel disease that affects the lining of the digestive tract, causing a wide range of gastrointestinal and systemic symptoms.
graph LR
Malnutrition["Malnutrition"]
TL1A_Mediated_T_Cell_Activation["TL1A-Mediated T Cell Activation"]
Myeloid_Stromal_Cell_Crosstalk["Myeloid-Stromal Cell Crosstalk"]
Diarrhea["Diarrhea"]
Weight_Loss["Weight Loss"]
Dehydration["Dehydration"]
Paneth_Cell_Autophagy_Impairment["Paneth Cell Autophagy Impairment"]
Antimicrobial_Defense_Deficiency["Antimicrobial Defense Deficiency"]
Myeloid_Cell_Recruitment_to_Perianal_Tissue["Myeloid Cell Recruitment to Perianal Tissue"]
Paneth_Cell_Autophagy_Impairment --> Antimicrobial_Defense_Deficiency
TL1A_Mediated_T_Cell_Activation --> Myeloid_Cell_Recruitment_to_Perianal_Tissue
Myeloid_Cell_Recruitment_to_Perianal_Tissue --> Myeloid_Stromal_Cell_Crosstalk
Diarrhea --> Weight_Loss
Diarrhea --> Malnutrition
Diarrhea --> Dehydration
style Malnutrition fill:#fef3c7
style TL1A_Mediated_T_Cell_Activation fill:#dbeafe
style Myeloid_Stromal_Cell_Crosstalk fill:#dbeafe
style Diarrhea fill:#fef3c7
style Weight_Loss fill:#fef3c7
style Dehydration fill:#fef3c7
style Paneth_Cell_Autophagy_Impairment fill:#dbeafe
style Antimicrobial_Defense_Deficiency fill:#dbeafe
style Myeloid_Cell_Recruitment_to_Perianal_Tissue fill:#dbeafe
name: Crohn Disease
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-02-16T20:19:38Z'
description: A chronic inflammatory bowel disease that affects the lining of the digestive tract, causing a wide range of gastrointestinal and systemic symptoms.
category: Complex
parents:
- Inflammatory Bowel Disease
- Autoimmune Disease
has_subtypes:
- name: Ileal Crohn's Disease
description: Involves inflammation of the ileum, the latter part of the small intestine.
evidence:
- reference: PMID:37377591
supports: SUPPORT
snippet: In CD, the ileum is frequently affected and about one third of patients presents with a pure ileal type.
explanation: This reference supports the statement that Crohn's disease involves inflammation of the ileum, and specifies this subtype as Ileal Crohn's Disease.
- reference: PMID:30882291
supports: SUPPORT
snippet: Gastroscopy revealed severe aphthous pangastritis with biopsies showing a focal active and chronic gastritis with presence of granulomas... coloscopy showing an aphthous terminal ileum... concordant with a slightly active, mildly chronic terminal ileitis typical for Crohn's disease.
explanation: This reference supports the claim that Crohn's disease can involve the ileum, characterizing it distinctly as terminal ileitis which is a known feature of Ileal Crohn's Disease.
- reference: PMID:31960900
supports: SUPPORT
snippet: Crohn''s disease patients with unequivocal imaging findings of ileal inflammation at enterography despite negative ileoscopy and biopsy are likely to have active inflammatory Crohn''s disease.
explanation: This reference highlights that Crohn's disease can manifest as inflammation of the ileum, aligning with the subtype of Ileal Crohn's Disease.
- name: Colonic Crohn's Disease
description: Affects the colon (large intestine) with skip lesions.
evidence:
- reference: PMID:38437854
supports: PARTIAL
snippet: Commonly affecting the terminal ileum and proximal colon, Crohn's disease inflammation is often discontinuous and patchy, segmental, and transmural.
explanation: The literature indicates that Crohn's disease can affect the colon and often presents with discontinuous, patchy inflammation. However, it is typically not limited to the colon and often involves the terminal ileum.
- reference: PMID:11271896
supports: SUPPORT
snippet: The site of involvement was the ileum in three patients, the colon in one patient and both the ileum and the colon in one patient. Typical small intestinal CD occurred in four of seven patients with marked aphthous lesions of the small intestine, whereas colonic CD occurred in two of eight patients with such aphthous lesions of the colon.
explanation: This study shows that Crohn's disease can indeed affect the colon specifically, supporting the subtype known as Colonic Crohn's Disease.
- reference: PMID:26906301
supports: PARTIAL
snippet: Although ileitis can be seen in HSP, terminal ileitis is virtually pathognomonic for Crohn disease.
explanation: The focus is on terminal ileitis, commonly seen in Crohn’s disease. It suggests that Crohn's disease frequently involves the ileum, but does not refute that the colon can also be involved.
- reference: PMID:33278326
supports: PARTIAL
snippet: Changes in absorptive capacity and first-pass metabolism in the small intestine affect oral drug bioavailability.
explanation: This study focuses on small intestine involvement in Crohn's disease but does not refute colonic involvement with skip lesions.
- reference: PMID:28379745
supports: NO_EVIDENCE
snippet: Nearly half (36/73, 49%) of the patients with normal or nonspecific findings at ileocolonoscopy had radiologically active disease with a median length of SB involvement of 20 cm (range, 1 to > 100 cm).
explanation: Findings indicate that Crohn's Disease can have varying and discontinuous involvement, including potentially just the colon, thereby supporting the subtype.
- name: Ileocolonic Crohn's Disease
description: Involves both the small intestine (ileum) and the colon.
evidence:
- reference: PMID:33712743
supports: PARTIAL
snippet: Crohn's disease can affect any part of the gastrointestinal tract; however, current European and national guidelines worldwide do not differentiate between small-intestinal and colonic Crohn's disease for medical treatment.
explanation: Although the literature acknowledges different manifestations of Crohn's disease involving the ileum and colon, it primarily discusses the broader differentiation between small-intestinal and colonic Crohn's Disease without naming or detailing specific subtypes such as Ileocolonic Crohn's Disease.
- reference: PMID:11271896
supports: PARTIAL
snippet: The site of involvement was the ileum in three patients, the colon in one patient and both the ileum and the colon in one patient.
explanation: This provides clinical evidence of Crohn's Disease affecting both the ileum and colon in patients but does not explicitly label it as Ileocolonic Crohn's Disease.
- reference: PMID:38294885
supports: SUPPORT
snippet: The terminal ileum and small bowel (SB) are involved in 30-45% of patients with Crohn's disease, while 20% have both small and large bowel involvement.
explanation: This literature reference supports the statement by noting that 20% of Crohn's disease cases involve both the small and large intestines, which corresponds to the description of Ileocolonic Crohn's Disease.
prevalence:
- population: Global
percentage: 0.2-0.3
evidence:
- reference: PMID:37137806
supports: WRONG_STATEMENT
snippet: The crude prevalence of IBD increased by 47% in 2019 globally.
explanation: The available literature does not provide specific data on the percentage prevalence of Crohn's Disease alone globally; it talks about the prevalence of IBD as a whole.
- reference: PMID:35930087
supports: NO_EVIDENCE
snippet: This prospective, observational registry study was conducted at 19 tertiary centers in Japan. Patients newly diagnosed with Crohn''s disease after June 2016 (age >/= 16 years at informed consent) were enrolled between December 17, 2018 and June 30, 2020.
explanation: This study focuses on the prevalence and characteristics of Crohn's Disease specifically in Japan, not globally.
progression:
- phase: Onset
age_range: 15-35
evidence:
- reference: PMID:33587489
supports: PARTIAL
snippet: Patients were divided into a derivation (80%) cohort and a validation (20%) cohort. The primary outcome was progressive disease... In our final model, age at diagnosis older than 60 years was significantly associated with a lower risk of developing progressive disease... In patients with CD.
explanation: The study indicates that younger patients, particularly those aged less than 60 years, are at higher risk of developing progressive Crohn's disease.
- reference: PMID:37384664
supports: REFUTE
snippet: Logistic regression analysis of the initial characteristics showed that the age at diagnosis, gender, initial location and initial extra-intestinal manifestation are not associated with the progression of the disease.
explanation: This study states that the progression of Crohn's disease is not linked to the initial age of diagnosis among children and adolescents.
- reference: PMID:37266570
supports: PARTIAL
snippet: The best predictive model (PREDICT-EPIMAD) included the location at diagnosis, pANCA, and 6 single nucleotide polymorphisms. This model showed good discrimination... Decision curve analysis confirmed the clinical utility of the model.
explanation: Though the exact age range of 15-35 is not specifically discussed, the predictive model includes various factors that can affect disease progression, which might encompass age-related variations.
- reference: PMID:28051217
supports: NO_EVIDENCE
snippet: Our aim was to identify the phenotype evolution of Crohn's disease over time according to the Montreal Classification and to precise predictive factors of the need for immunosuppressant treatment or surgery... without association with age, sex or smoking habits.
explanation: This study did not find evidence associating age with the progression of Crohn's disease, focusing instead on phenotype and specific disease markers.
pathophysiology:
- name: Dysregulated Immune Response
description: The immune system attacks the gastrointestinal tract, leading to chronic inflammation.
evidence:
- reference: PMID:32242028
supports: SUPPORT
snippet: Several factors have been implicated in the cause of Crohn's disease, including a dysregulated immune system, an altered microbiota, genetic susceptibility and environmental factors, but the cause of the disease remains unknown.
explanation: The statement is supported as one of the major factors causing Crohn's Disease is the dysregulated immune system attacking the gastrointestinal tract.
- reference: PMID:36720220
supports: PARTIAL
snippet: Crohn's disease (CD) is a chronic gastrointestinal disease that is increasing in prevalence worldwide. CD is multifactorial, involving the complex interplay of genetic, immune, and environmental factors... we mapped markers of disease-associated myofibroblast activation and identified CHMP1A, TBX3, and RNF168 as regulators of fibrotic complications.
explanation: This study supports the mechanism involving the immune system leading to inflammation and chronic disease in the gastrointestinal tract.
- reference: PMID:21543977
supports: SUPPORT
snippet: The lymphatic system is re-emerging as a critical player in inflammatory and immune processes... Recent studies reporting lymphangitis, lymphangiogenesis, bacterial infiltration and lymph node infection, immune cell trafficking, and fat-wrapping in Crohn's disease suggest altered lymph drainage and lymphatic pumping, implicating the lymphatic system as a likely player in inflammatory disorders and IBDs.
explanation: The literature acknowledges the immune system's involvement in Crohn's Disease through various mechanisms, including lymphatic system dysfunction.
- name: Microbiome Imbalance
description: Alterations in gut microbiota contribute to the disease mechanisms.
evidence:
- reference: PMID:34313550
supports: SUPPORT
snippet: Crohn's disease (CD) is a major form of inflammatory bowel disease characterized by transmural inflammation along the alimentary tract. Changes in the microbial composition and reduction in species diversity are recognized as pivotal hallmarks in disease dynamics, challenging the gut barrier function and shaping a pathological immune response in genetically influenced subjects.
explanation: This study details changes in microbial composition and reduction in species diversity as key factors in the dynamics of Crohn's Disease, thereby supporting the statement.
- reference: PMID:18810765
supports: SUPPORT
snippet: This ileal and colonic defect in innate defence mediated by a deficiency of the protective alpha- and beta-defensins may enable the luminal microbes to invade the mucosa and trigger the inflammation.
explanation: This study indicates that defects in innate defense mechanisms allow microbial invasion, which triggers inflammation, supporting the involvement of microbiota alterations in Crohn's Disease.
- reference: PMID:23971750
supports: SUPPORT
snippet: Inflammatory bowel disease includes ulcerative colitis and Crohn's disease, which are both inflammatory disorders of the gastrointestinal tract. Both types of inflammatory bowel disease have a complex etiology, resulting from a genetically determined susceptibility interacting with environmental factors, including the diet and gut microbiota.
explanation: This article mentions the role of gut microbiota as an environmental factor in the etiology of Crohn's Disease, supporting the contribution of microbiome imbalance to disease mechanisms.
- name: Paneth Cell Autophagy Impairment
description: Defective autophagy in Paneth cells due to mutations in autophagy genes (ATG16L1, ATG5) causes abnormal granule formation and impaired antimicrobial peptide secretion.
cell_types:
- preferred_term: Paneth cell
term:
id: CL:0000510
label: paneth cell
biological_processes:
- preferred_term: Autophagy
term:
id: GO:0006914
label: autophagy
locations:
- preferred_term: Terminal ileum
term:
id: UBERON:0001211
label: ileum
downstream:
- target: Antimicrobial Defense Deficiency
description: Loss of Paneth cell granule secretion reduces antimicrobial peptide levels in intestinal lumen.
evidence:
- reference: PMID:18849966
supports: SUPPORT
snippet: ATG16L1- and ATG5-deficient Paneth cells exhibited notable abnormalities in the granule exocytosis pathway
explanation: This study demonstrates that autophagy proteins ATG16L1 and ATG5 are essential for Paneth cell function and that defects cause granule abnormalities linked to Crohn's disease.
- name: Antimicrobial Defense Deficiency
description: Reduced secretion of antimicrobial peptides (defensins, lysozyme) allows increased bacterial translocation across the intestinal epithelium.
biological_processes:
- preferred_term: Antimicrobial humoral response
term:
id: GO:0019730
label: antimicrobial humoral response
locations:
- preferred_term: Terminal ileum
term:
id: UBERON:0001211
label: ileum
- name: Macrophage Autophagy Dysfunction
description: Impaired autophagy in lamina propria macrophages leads to defective clearance of intracellular bacteria and inflammatory cytokine release.
cell_types:
- preferred_term: Macrophage
term:
id: CL:0000235
label: macrophage
biological_processes:
- preferred_term: Autophagy
term:
id: GO:0006914
label: autophagy
locations:
- preferred_term: Intestinal lamina propria
term:
id: UBERON:0011878
label: lamina propria of small intestine
- name: IL-23/Th17 Axis Dysregulation
description: Overactive IL-23 signaling drives pathogenic Th17 cell differentiation and chronic intestinal inflammation.
cell_types:
- preferred_term: Th17 cell
term:
id: CL:0000899
label: T-helper 17 cell
- preferred_term: Dendritic cell
term:
id: CL:0000451
label: dendritic cell
biological_processes:
- preferred_term: Th17 cell differentiation
term:
id: GO:0072538
label: T-helper 17 type immune response
- preferred_term: IL-23 signaling
locations:
- preferred_term: Intestinal mucosa
term:
id: UBERON:0001211
label: ileum
- name: Fibrosis and Stricture Formation
description: Chronic inflammation leads to fibroblast activation, extracellular matrix deposition, and intestinal strictures.
cell_types:
- preferred_term: Fibroblast
term:
id: CL:0000057
label: fibroblast
- preferred_term: Myofibroblast
term:
id: CL:0000186
label: myofibroblast cell
biological_processes:
- preferred_term: Extracellular matrix organization
term:
id: GO:0030198
label: extracellular matrix organization
- preferred_term: Tissue remodeling
term:
id: GO:0048771
label: tissue remodeling
locations:
- preferred_term: Intestinal wall
term:
id: UBERON:0001262
label: wall of intestine
- preferred_term: Mesenteric adipose tissue
term:
id: UBERON:0003427
label: mesenteric fat pad
- name: TL1A-Mediated T Cell Activation
description: Tumor necrosis factor-like ligand 1A (TL1A) activates T cells through death receptor 3 (DR3), promoting inflammatory cytokine production and recruitment of myeloid cells to sites of tissue damage.
cell_types:
- preferred_term: T cell
term:
id: CL:0000084
label: T cell
biological_processes:
- preferred_term: T cell activation
term:
id: GO:0042110
label: T cell activation
locations:
- preferred_term: Rectal mucosa
term:
id: UBERON:0003346
label: rectal mucosa
downstream:
- target: Myeloid Cell Recruitment to Perianal Tissue
description: Activated T cells produce chemokines that recruit macrophages to perianal inflammatory sites.
- name: Myeloid Cell Recruitment to Perianal Tissue
description: Chemokine-driven infiltration of macrophages and other myeloid cells into perianal tissues, establishing chronic inflammation.
cell_types:
- preferred_term: Macrophage
term:
id: CL:0000235
label: macrophage
biological_processes:
- preferred_term: Leukocyte migration
term:
id: GO:0050900
label: leukocyte migration
locations:
- preferred_term: Perianal region
term:
id: UBERON:0012336
label: perianal space
downstream:
- target: Myeloid-Stromal Cell Crosstalk
description: Recruited macrophages interact with resident fibroblasts, driving tissue remodeling.
- name: Myeloid-Stromal Cell Crosstalk
description: Interferon-driven macrophage activation promotes fibroblast activation and matrix degradation, creating tissue disruption that leads to fistula tract formation.
cell_types:
- preferred_term: Macrophage
term:
id: CL:0000235
label: macrophage
- preferred_term: Fibroblast
term:
id: CL:0000057
label: fibroblast
biological_processes:
- preferred_term: Type II interferon signaling
term:
id: GO:0060337
label: type I interferon signaling pathway
locations:
- preferred_term: Perianal region
term:
id: UBERON:0012336
label: perianal space
phenotypes:
- category: Gastrointestinal
name: Abdominal Pain
frequency: VERY_FREQUENT
evidence:
- reference: PMID:29246562
supports: SUPPORT
snippet: The most frequent symptoms are abdominal pain and diarrhoea, which can seriously affect patients' quality of life.
- reference: PMID:33946069
supports: SUPPORT
snippet: In Crohn's disease, inflammation causes pain.
- reference: PMID:35380673
supports: SUPPORT
snippet: The prevalence of pain was high in IBD patients ... and higher in CD patients.
- reference: PMID:33836648
supports: NO_EVIDENCE
snippet: Using the patients'' self-reported information, we identified two subpopulations of Crohn's disease; these subpopulations differ in disease severity, associations with smoking, and genetic transmission patterns.
explanation: While this reference focuses on identifying subpopulations with varying disease severity, it underscores the heterogeneity of Crohn’s disease symptoms, indirectly supporting that abdominal pain is a frequent symptom.
diagnostic: true
notes: Often occurs in the right lower quadrant
phenotype_term:
preferred_term: Abdominal pain
term:
id: HP:0002027
label: Abdominal pain
- category: Gastrointestinal
name: Diarrhea
frequency: VERY_FREQUENT
diagnostic: true
sequelae:
- target: Weight Loss
- target: Malnutrition
- target: Dehydration
evidence:
- reference: PMID:22230271
supports: PARTIAL
snippet: Patients may experience diarrhea, abdominal pain, fever, weight loss, abdominal masses, and anemia.
explanation: This reference supports the presence of diarrhea and weight loss as frequent symptoms of Crohn's disease. However, it does not explicitly discuss malnutrition as a common sequela or confirm that these phenotypes are highly frequent.
- reference: PMID:38036713
supports: PARTIAL
snippet: Malnutrition might play a key role in the prognosis of patients with Crohn's disease (CD) ... Forty-one patients (24.8%) had body weight loss whereas 124 patients (75.2%) had no body weight loss.
explanation: This reference mentions weight loss and suggests a role for malnutrition in Crohn's disease prognosis, but does not confirm high frequency of gastrointestinal symptoms like diarrhea.
notes: Can be bloody or non-bloody
phenotype_term:
preferred_term: Diarrhea
term:
id: HP:0002014
label: Diarrhea
- category: Systemic
name: Fatigue
frequency: FREQUENT
evidence:
- reference: PMID:23111414
supports: SUPPORT
snippet: A high percentage of CD patients suffer from fatigue.
explanation: This reference confirms that fatigue is a common symptom among Crohn's disease patients.
- reference: PMID:37569413
supports: SUPPORT
snippet: Despite high prevalence and importance, the symptom is often underestimated in clinical practice.
explanation: The reference articulates the high prevalence of fatigue in inflammatory diseases, supporting the statement that fatigue is common among Crohn's disease patients.
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
- category: Gastrointestinal
frequency: OCCASIONAL
name: Perianal Disease
notes: Fistulas, abscesses, skin tags
evidence:
- reference: PMID:15227686
supports: PARTIAL
snippet: Perianal Crohn's disease can manifest as skin tags, ulcers, fissures, abscesses, fistulas or stenoses.
explanation: The literature supports that perianal disease is a manifestation of Crohn's disease and lists fistulas, abscesses, and skin tags as possible manifestations. However, it does not specifically address the frequency as 'occasional'.
- reference: PMID:15711045
supports: PARTIAL
snippet: Fistulas are common in Crohn's disease. A population-based study has shown a cumulative risk of 33% after 10 years and 50% after 20 years. Perianal fistulas were the most common (54%).
explanation: The literature indicates that perianal fistulas are common in Crohn's disease, which suggests a higher frequency than 'occasional'.
- reference: PMID:33280851
supports: PARTIAL
snippet: Of children presenting with a perianal symptom, three percent will eventually be diagnosed with CD. At highest risk (35%) were males aged 10 years or older with a perianal fistula.
explanation: The literature supports that perianal symptoms can be an initial presentation of Crohn's disease in children, but it does not specify the frequency as 'occasional'.
- category: Gastrointestinal
frequency: OCCASIONAL
name: Intestinal Obstruction
notes: Due to stricturing disease
evidence:
- reference: PMID:29043578
supports: SUPPORT
snippet: The most common phenotype is stricturing disease which can lead to obstructive-like symptoms.
explanation: The reference states that stricturing disease, a common phenotype of Crohn's disease, can lead to obstructive-like symptoms, supporting the statement that intestinal obstruction due to stricturing disease occurs occasionally in Crohn's disease.
- reference: PMID:34014617
supports: SUPPORT
snippet: Approximately 70% of patients inevitably develop fibrosis-associated intestinal stricture after 10 years of CD diagnosis, which seriously affects their quality of life.
explanation: The reference indicates that a significant proportion of Crohn's disease patients develop intestinal strictures, which can lead to obstruction, supporting the statement.
- reference: PMID:37973225
supports: SUPPORT
snippet: Benign etiologies of colonic obstructions include...inflammatory processes such as Crohn's disease.
explanation: The reference confirms that inflammatory processes like Crohn's disease can lead to colonic obstructions, supporting the statement.
phenotype_term:
preferred_term: Intestinal Obstruction
term:
id: HP:0004796
label: Gastrointestinal obstruction
- category: Musculoskeletal
frequency: OCCASIONAL
name: Arthritis
notes: Can affect both large and small joints
evidence:
- reference: PMID:21122514
supports: SUPPORT
snippet: The most common extraintestinal manifestation, articular involvement, occurs in 16% to 33% of inflammatory bowel disease patients. These arthropathies may increase morbidity, resulting in a worse quality of life compared with inflammatory bowel disease patients without arthropathies.
explanation: The literature indicates that arthritis is a common extraintestinal manifestation of Crohn's disease, affecting both large and small joints.
- reference: PMID:36730654
supports: SUPPORT
snippet: The prevalence of peripheral arthritis was significantly higher in CD-FMF group (37.5% vs. 10.4%, respectively, P =0.04).
explanation: This study supports the occurrence of arthritis in Crohn's disease patients, particularly noting a higher prevalence in patients with coexisting FMF.
phenotype_term:
preferred_term: Arthritis
term:
id: HP:0001369
label: Arthritis
- category: Dermatologic
frequency: OCCASIONAL
name: Erythema Nodosum
notes: Painful nodules on shins
evidence:
- reference: PMID:16143688
supports: SUPPORT
snippet: Erythema nodosum is a common cause of tender red nodules of the shins. Management includes leg elevation, NSAIDs, and potassium iodide.
explanation: The reference confirms that erythema nodosum, characterized by tender red nodules on the shins, is associated with inflammatory bowel disease, which includes Crohn's disease.
- reference: PMID:24746312
supports: SUPPORT
snippet: Erythema nodosum (EN) is clinically the most frequent form of panniculitis and is considered a reactive process that may be triggered by a wide variety of stimuli. Whilst up to 55% of EN is considered idiopathic, the most common causes include infections, drugs, systemic illnesses such as sarcoidosis and inflammatory bowel disease, pregnancy, and malignancy.
explanation: The reference supports the statement by mentioning that erythema nodosum is commonly triggered by systemic illnesses, including inflammatory bowel disease, which encompasses Crohn's disease.
phenotype_term:
preferred_term: Erythema Nodosum
term:
id: HP:0012219
label: Erythema nodosum
- category: Ocular
frequency: OCCASIONAL
name: Uveitis
notes: Inflammation of the eye
evidence:
- reference: PMID:2052301
supports: PARTIAL
snippet: Seven patients had uveitis, eight had episcleritis, and four had anterior scleritis.
explanation: The literature confirms that uveitis is a type of ocular inflammation associated with Crohn's disease, but it does not specify the frequency as 'occasional'.
- reference: PMID:29102673
supports: PARTIAL
snippet: This case of Crohn's disease and uveitis is unusual in that ocular inflammation preceded intestinal involvement, with the atypical feature of chronic intermediate uveitis.
explanation: The literature provides a case of uveitis associated with Crohn's disease but does not specify the frequency as 'occasional'.
phenotype_term:
preferred_term: Uveitis
term:
id: HP:0000554
label: Uveitis
- category: Systemic
frequency: FREQUENT
name: Fatigue
notes: Often worsened during disease flares
evidence:
- reference: PMID:20456309
supports: SUPPORT
snippet: Fatigue is common, disabling yet underappreciated, in patients with chronic diseases, including inflammatory bowel disease (IBD).
explanation: The literature explicitly states that fatigue is common in IBD, which includes Crohn's Disease.
- reference: PMID:17560419
supports: PARTIAL
snippet: Pain and depression are associated with inflammatory bowel disease, and their control benefits patients.
explanation: This reference mentions pain and depression as associated with IBD but does not specifically mention fatigue. However, the association with other systemic symptoms suggests a partial support.
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
- category: Systemic
frequency: OCCASIONAL
name: Fever
notes: More common during acute flares
evidence:
- reference: PMID:30244270
supports: SUPPORT
snippet: Crohn's disease is a chronic inflammatory bowel disease. The disease is characterized by acute exacerbations with diarrhea, abdominal pain, fever, anorexia, intestinal bleeding, and weight loss.
explanation: This reference confirms that fever is a symptom associated with acute exacerbations of Crohn's disease.
- reference: PMID:921308
supports: SUPPORT
snippet: In 32 patients with Crohn's disease which started in childhood, abdominal pain, diarrhoea, and weight loss were the common presenting symptoms, but unexplained fever and failure to grow were also prominent.
explanation: This reference supports the statement by indicating that fever is a prominent symptom in patients with Crohn's disease.
- reference: PMID:27743896
supports: SUPPORT
snippet: A frequent problem in CD is the discrimination of fever caused by exacerbated bowel inflammation or IAA.
explanation: This reference supports the statement by highlighting that fever is a frequent issue in Crohn's disease, especially during exacerbations.
- reference: PMID:31347993
supports: SUPPORT
snippet: A 23-year-old man with a known history of Crohn's disease (CD), who underwent an ileocaecal resection for localized disease activity three months ago, suffered from persistent fever with chills since 10 days.
explanation: This reference supports the statement by providing a case where a patient with Crohn's disease experienced persistent fever.
phenotype_term:
preferred_term: Fever
term:
id: HP:0001945
label: Fever
- category: Systemic
name: Weight Loss
frequency: FREQUENT
phenotype_term:
preferred_term: Weight Loss
term:
id: HP:0001824
label: Weight loss
- category: Systemic
name: Malnutrition
frequency: FREQUENT
phenotype_term:
preferred_term: Malnutrition
term:
id: HP:0004395
label: Malnutrition
- category: Systemic
name: Dehydration
frequency: FREQUENT
phenotype_term:
preferred_term: Dehydration
term:
id: HP:0001944
label: Dehydration
- category: Gastrointestinal
name: Intestinal Stricture
frequency: FREQUENT
notes: Approximately 35% of patients develop intestinal strictures; complications requiring surgery occur in up to 70% within 10 years. Fibrostenotic disease manifestation.
- category: Gastrointestinal
name: Perianal Fistula
frequency: FREQUENT
notes: Occurs in approximately 20-50% of Crohn's disease patients; often requires surgical intervention. Related to perianal abscess formation.
phenotype_term:
preferred_term: Perianal abscess
term:
id: HP:0009789
label: Perianal abscess
- category: Gastrointestinal
name: Transmural Inflammation
frequency: VERY_FREQUENT
notes: Characteristic feature of Crohn's disease affecting all layers of the intestinal wall.
diagnostic: true
phenotype_term:
preferred_term: Intestinal inflammation
biochemical:
- name: C-Reactive Protein (CRP)
presence: Elevated
evidence:
- reference: PMID:24635486
supports: SUPPORT
snippet: C-reactive protein (CRP) is an important acute-phase marker, produced mainly in the liver. Its production by mesenteric adipocytes has been recently stressed in Crohn's disease (CD).
explanation: The literature indicates that CRP is a relevant marker for inflammation in Crohn's Disease.
- reference: PMID:22868800
supports: SUPPORT
snippet: 'MDA/TBARS were the best predictor of CD, comparable to CRP, with high specificity (MDA/TBARS sensitivity and specificity: 75% and 90%; CRP: 76% and 93%). Combined assessment of MDA/TBARS and CRP improved sensitivity (94%) corresponding with acceptable specificity (81%).'
explanation: The study highlights that CRP is a reliable biochemical marker for Crohn's Disease, confirming its elevated presence.
- reference: PMID:36550821
supports: SUPPORT
snippet: C-reactive protein, vitamin B12, folate levels were studied along with hemogram analyses.
explanation: This study further supports that CRP levels are relevant in the context of Crohn's Disease.
context: General inflammation
- name: Fecal Calprotectin
presence: Elevated
context: Intestinal inflammation
evidence:
- reference: PMID:31088326
supports: SUPPORT
snippet: Calprotectin, a cytosolic protein derived predominantly from neutrophils, is now widely used in this capacity. Calprotectin is found in various bodily fluids at concentrations proportional to the degree of inflammation, including in feces at levels roughly six times higher than in the blood. Fecal calprotectin (FCP) therefore reflects intestinal inflammation.
explanation: The statement is supported by the literature, which indicates that fecal calprotectin levels are elevated in the context of intestinal inflammation, consistent with the presence of Crohn's Disease.
genetic:
- name: NOD2
association: Risk Factor
evidence:
- reference: PMID:29358789
supports: SUPPORT
snippet: 'BACKGROUND AND OBJECTIVES: Crohn''s disease is a multifactorial inflammatory disease affecting mainly the gastrointestinal tract. The genetic factors that are involved in the disease include mainly three mutations of the gene NOD2/CARD15 (R702W, G908R, 3020insC).'
explanation: This reference states that NOD2 mutations are involved in Crohn's disease, supporting the association as a risk factor.
- reference: PMID:23352252
supports: SUPPORT
snippet: NOD2 gene mutations are associated with several diseases, and some of the mutations are of diagnostic value in Blau disease and NAID... The NOD2 variants located in the leucine-rich repeat (LRR) region are susceptible to Crohn disease.
explanation: This reference confirms the association of NOD2 gene mutations with Crohn's disease.
- reference: PMID:16773683
supports: SUPPORT
snippet: Investigations into the inheritance of the three risk alleles R702W, G908R and 1007fsInsC in NOD2 associated with susceptibility to Crohn's disease have demonstrated a remarkable amount of heterogeneity across ethnicities and populations.
explanation: This reference clearly establishes the association of specific NOD2 mutations with susceptibility to Crohn's disease.
- reference: PMID:12851870
supports: SUPPORT
snippet: The NOD2 gene, which is strongly associated with susceptibility to Crohn's disease (CD) of the terminal ileum, interacts with bacterial lipopolysaccharide (LPS), inducing cellular activation.
explanation: This study supports the role of NOD2 as a genetic risk factor for Crohn's disease.
- reference: PMID:32476786
supports: SUPPORT
snippet: While NOD2 mutations represent well established risk factors of CD, the role of other genes is incompletely understood.
explanation: This confirms that NOD2 is a well-established genetic risk factor for Crohn's disease.
- reference: PMID:11385577
supports: SUPPORT
snippet: Here we show, by using the transmission disequilibium test and case-control analysis, that a frameshift mutation caused by a cytosine insertion, 3020insC, which is expected to encode a truncated NOD2 protein, is associated with Crohn's disease.
explanation: This study provides evidence of a specific NOD2 mutation associated with Crohn's disease.
- reference: PMID:17206682
supports: SUPPORT
snippet: The association of NOD2/CARD15 mutations with CD and BS, and possibly also early onset sarcoidosis, suggests a role for the gene in the development of granulomata and granulomatous diseases.
explanation: This statement supports the association of NOD2 with Crohn's disease (CD).
- reference: PMID:16987083
supports: SUPPORT
snippet: The mapping to CD of Nod2 variants that alter protein function represents one of the earliest, most well-established, associations in complex genetic disorders.
explanation: This reference emphasizes that the NOD2 association with Crohn's disease is well-established.
- reference: PMID:27076762
supports: SUPPORT
snippet: The highest accuracy, AUC of 0.78 was achieved with GRS combining 33 SNPs with optimal sensitivity and specificity of 75.0% and 72.7%, respectively.
explanation: This study confirms the role of genetic risk scores including multiple SNP variants for predicting Crohn's disease.
- name: ATG16L1
association: Risk Factor
evidence:
- reference: PMID:27698206
supports: SUPPORT
snippet: Conclusion In this meta-analysis, the ATG16L1 genotype was significantly associated with the risk of developing Crohn''s disease.
- reference: PMID:25906181
supports: SUPPORT
snippet: single-nucleotide polymorphisms in ATG16L1 ... a key component in the autophagic response to invading pathogens, have been associated with an increased risk of developing Crohn disease.
- reference: PMID:12840668
supports: NO_EVIDENCE
snippet: CARD15 mutations are present in 30-50% of CD patients compared to 7-20% of healthy controls. Interestingly, CD patients often carry mutations on their two chromosomes suggesting a mutation dose effect.
explanation: The reference focuses on the association between CARD15 mutations and Crohn’s Disease, with no information regarding ATG16L1.
- reference: PMID:29795570
supports: NO_EVIDENCE
snippet: ten rare genetic risk factors in NOD2 and LRRK2 are enriched in AJ (p < 0.005), including several novel contributing alleles, show evidence of association to CD.
explanation: The reference highlights genetic risk factors in NOD2 and LRRK2 for Crohn's Disease, not ATG16L1.
- reference: PMID:27076762
supports: PARTIAL
snippet: We generated genetic risk scores (GRS) based on the number of risk alleles using weighted additive model. Discriminatory accuracy was measured by area under ROC curve (AUC)....The highest accuracy, AUC of 0.78 was achieved with GRS combining 33 SNPs with optimal sensitivity and specificity of 75.0% and 72.7%, respectively.
explanation: The study involves identification of SNPs for risk prediction, however ATG16L1 is not mentioned explicitly. Thus, it only partially supports the statement.
- name: IL23R
association: Risk Factor
evidence:
- reference: PMID:17068223
supports: SUPPORT
snippet: We found a highly significant association between Crohn's disease and the IL23R gene on chromosome 1p31, which encodes a subunit of the receptor for the proinflammatory cytokine interleukin-23.
explanation: This study identifies IL23R as a gene significantly associated with Crohn's disease, supporting the statement that IL23R is a genetic risk factor for the condition.
- reference: PMID:24989722
supports: SUPPORT
snippet: We demonstrate a strong increased CD risk for smokers in both datasets (odds ratio 3.77, 95% confidence interval 2.88-4.94), and an additive interaction between IL23R SNPs and cigarette smoking.
explanation: This study supports the association between IL23R and Crohn's disease, while also highlighting the interaction between IL23R variants and environmental factors like smoking.
- name: LRRK2
association: Risk Factor
notes: Hyperactive LRRK2 variants (e.g., G2019S, N2081D) impair autophagy and drive Paneth-cell dysfunction, leading to intestinal inflammation.
- name: TNFSF15
association: Risk Factor
notes: Encodes TL1A, a TNF superfamily cytokine involved in T-cell costimulation and fibroblast activation in fistulizing disease.
- name: CARD9
association: Risk Factor
notes: Involved in antifungal immunity; variants associated with fungal dysbiosis and impaired pathogen clearance.
- name: BACH2
association: GWAS
notes: Transcription factor regulating Treg/effector T cell balance and B cell class switching
- name: TNFAIP3
association: GWAS
notes: Encodes A20, a ubiquitin-editing enzyme that negatively regulates NF-kB signaling
- name: STAT3
association: GWAS
notes: Signal transducer mediating Th17 differentiation via JAK-STAT pathway
- name: IL10
association: GWAS
notes: Anti-inflammatory cytokine critical for immune tolerance
- name: CD28
association: GWAS
notes: T cell co-stimulatory receptor required for T cell activation
- name: EGR2
association: GWAS
notes: Transcription factor involved in T cell anergy and peripheral tolerance
- name: ETS1
association: GWAS
notes: Transcription factor regulating T and B cell development and immune cell differentiation
- name: IRF4
association: GWAS
notes: Transcription factor essential for Th17 and Th2 cell differentiation and plasma cell development
- name: IRF8
association: GWAS
notes: Interferon regulatory factor controlling myeloid cell development and type I interferon response
- name: SATB1
association: GWAS
notes: Chromatin organizer regulating T cell development and lineage commitment
- name: IKZF1
association: GWAS
notes: Ikaros transcription factor essential for lymphocyte development and differentiation
- name: SMAD3
association: GWAS
notes: TGF-beta signaling mediator regulating T cell differentiation and immune tolerance
- name: PRDM1
association: GWAS
notes: Blimp-1 transcription factor regulating T cell and B cell terminal differentiation
- name: PTPN22
association: GWAS
notes: Protein tyrosine phosphatase modulating T cell receptor signaling threshold
- name: IL21R
association: GWAS
notes: IL-21 receptor mediating T and B cell activation and differentiation
environmental:
- name: Smoking
notes: Increases the risk and severity of Crohn's disease.
evidence:
- reference: PMID:27016849
supports: SUPPORT
snippet: Smoking increases the risk of complications, recurrences and resort of surgery, corticosteroids or immunosuppressants.
explanation: The provided literature clearly states that smoking increases the risk and severity of Crohn's disease, aligning with the statement.
- reference: PMID:31014995
supports: SUPPORT
snippet: 'We identified 9 factors that increase risk of IBD: smoking (CD)...'
explanation: The review identifies smoking as a significant environmental risk factor that increases the risk of Crohn's disease.
- reference: PMID:38238335
supports: SUPPORT
snippet: Compared to never smoking, current and previous smoking habits are associated with increased CD (P = 7.09 Ă— 10-10) and UC (P < 2 Ă— 10-16) risk, respectively.
explanation: This prospective cohort study finds that both current and previous smoking habits are associated with increased risk of CD, which supports the statement.
- reference: PMID:28838409
supports: SUPPORT
snippet: Understanding the potential environmental risk factors and natural history of CD in a given patient guides the physician when counseling the patient and selecting a treatment strategy.
explanation: The review discusses smoking as an important environmental risk factor, thereby supporting the statement.
exposure_term:
preferred_term: Tobacco smoking exposure
term:
id: ECTO:6000029
label: exposure to tobacco smoking
- name: Diet
notes: Western diet with high-fat, low-fiber content may exacerbate symptoms.
evidence:
- reference: PMID:33574618
supports: SUPPORT
snippet: Fiber-poor Western diets fuel inflammation.
explanation: This indicates that a Western diet, which is low in fiber, can contribute to inflammation, suggesting a potential exacerbation of symptoms in Crohn's Disease.
- reference: PMID:34010595
supports: SUPPORT
snippet: In mouse models, consumption of a WD for as little as 4 weeks led to Paneth cell dysfunction.
explanation: This study provides a direct mechanistic link between a Western diet and compromised gut immunity, which could exacerbate Crohn's disease symptoms.
- reference: PMID:33159156
supports: SUPPORT
snippet: Our results indicated that, among lifestyle exposures, being a smoker was positively associated with CD (OR 1.13, P = 0.02).
explanation: This Mendelian randomization study shows lifestyle factors including diet-related factors affect Crohn's disease risk.
- reference: PMID:35595417
supports: PARTIAL
snippet: most patients report minimal nutritional education from their provider, and providers report few nutritional resources to help them educate patients.
explanation: While this indicates the importance of diet, it also highlights a lack of resources and education surrounding the dietary management of Crohn's disease, providing partial support.
exposure_term:
preferred_term: Dietary exposure
- name: Stress
notes: Can trigger flare-ups and worsen symptoms.
evidence:
- reference: PMID:15288007
supports: NO_EVIDENCE
snippet: Stress is also associated with IBD, but more as a modifier than an inducing factor, and its contribution is more obvious in IBD animal models than human IBD.
explanation: The literature suggests that stress is associated with IBD as a modifier and not necessarily as a direct trigger.
- reference: PMID:31574072
supports: SUPPORT
snippet: The unpredictable course of the disease, impaired function due to fatigue, and lack of bowel control were the most prominent causes of worry. The worries created feelings of stress, guilt, and frustration. The participants expressed a need to talk about their worries, to make them visible and recognized, and to be understood.
explanation: The study indicates that stress related to the disease itself is significant among Crohn's disease patients, which supports the claim that stress can worsen symptoms.
exposure_term:
preferred_term: Psychological stress exposure
treatments:
- name: Aminosalicylates
description: Anti-inflammatory drugs used for mild to moderate disease.
evidence:
- reference: PMID:12786608
supports: SUPPORT
snippet: The mainstay of current medical treatment for mild to moderately active stages of Crohn's disease includes aminosalicylates, antibiotics, glucococorticosteroids and immunomodulators.
explanation: This reference states that aminosalicylates are included in the main treatments for mild to moderately active Crohn's disease.
- reference: PMID:34797442
supports: SUPPORT
snippet: 5-aminosalicylates (5-ASA) are frequently used in the management of Crohn's disease.
explanation: This reference supports the use of aminosalicylates for Crohn's disease treatment.
- reference: PMID:17339853
supports: REFUTE
snippet: Sulfasalazine and mesalazine are useful for the treatment of both active and quiescent ulcerative colitis, whereas they have no clinical effect on either active or inactive Crohn's disease.
explanation: This reference explicitly states that aminosalicylates have no clinical effect on Crohn's disease.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
- name: Corticosteroids
description: Used for short-term control during flare-ups to reduce inflammation.
evidence:
- reference: PMID:24532122
supports: SUPPORT
snippet: Corticosteroids have been used for decades to treat active Crohn's disease and remain the mainstay in the management of moderate-to-severe relapses in Crohn's disease.
explanation: This indicates that corticosteroids are indeed a primary treatment option for managing flare-ups in Crohn's disease.
- reference: PMID:32653651
supports: SUPPORT
snippet: corticosteroids are crucial for the induction of remission of moderate‑to‑severe flares in both UC and Crohn's disease.
explanation: This strengthens the claim that corticosteroids are used for short-term control during flare-ups to reduce inflammation in Crohn's disease.
- reference: PMID:18239408
supports: SUPPORT
snippet: The management of Crohn's disease usually consists of a succession of short-term acute phase treatments followed by a long-term maintenance therapy.
explanation: This reinforces that corticosteroids are part of the short-term treatment strategy to control flare-ups in Crohn's disease.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
- name: Immunomodulators
description: Drugs like azathioprine and methotrexate to suppress the immune response.
evidence:
- reference: PMID:17105689
supports: SUPPORT
snippet: The immunomodulatory drugs in the IBD arsenal include azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, and tacrolimus.
explanation: The provided literature supports the statement that drugs like azathioprine and methotrexate are used as immunomodulators to manage Crohn's Disease.
- reference: PMID:35115294
supports: SUPPORT
snippet: Our results show that parenteral use of methotrexate is efficacious in inducing and maintaining remission as a step-up agent in azathioprine refractory Crohn's disease patients.
explanation: The study shows the use of methotrexate in patients who are refractory to azathioprine, supporting the statement that these drugs are used to treat Crohn's Disease by mitigating immune response.
- reference: PMID:16245637
supports: SUPPORT
snippet: First line immunosuppressants are Azathioprine and 6-Mercaptopurine while Methotrexate, Infliximab, Mycophenolatmofetil and other compounds represent alternative or rescue medications.
explanation: This reference confirms that Azathioprine and Methotrexate are used as immunosuppressants in the treatment of Crohn's Disease.
- reference: PMID:24913384
supports: SUPPORT
snippet: The only other long term disease-modifying options are the immunomodulators, methotrexate, azathioprine and mercaptopurine.
explanation: This review supports the use of methotrexate and azathioprine as immunomodulators for long-term management of Crohn's Disease.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
- name: Biologics
description: Anti-TNF agents (infliximab, adalimumab) and integrin inhibitors (vedolizumab) for moderate to severe disease.
evidence:
- reference: PMID:18034589
supports: PARTIAL
snippet: Infliximab and adalimumab are currently the only biological agents approved for induction and maintenance treatment in adults (infliximab and adalimumab) and children (infliximab) with Crohn's disease.
explanation: This reference supports the use of anti-TNF agents (infliximab and adalimumab) for the treatment of moderate to severe Crohn's disease but does not mention vedolizumab directly.
- reference: PMID:26195652
supports: PARTIAL
snippet: Vedolizumab is an integrin-receptor antagonist for the treatment of CD and UC in adults with moderately to severely active disease.
explanation: This reference supports the use of vedolizumab (an integrin inhibitor) for the treatment of Crohn's disease but does not provide details on anti-TNF agents (infliximab and adalimumab).
- reference: PMID:26616476
supports: SUPPORT
snippet: Anti-TNF-alpha therapy is a novel approach that has transformed the way moderate-to-severe Crohn's disease (CD) is treated and has significantly improved clinical outcomes of patients.
explanation: This reference supports the use of anti-TNF agents for moderate to severe Crohn's disease.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
- name: Nutritional Therapy
description: Dietary modifications and enteral nutrition to manage symptoms and maintain nutrition.
evidence:
- reference: PMID:19244154
supports: SUPPORT
snippet: Nutrition therapy of Crohn's disease is considered the first-line of treatment for Crohn's disease in children, especially in Europe.
explanation: This article supports the use of nutrition therapy as a treatment for managing symptoms and maintaining nutrition in Crohn’s disease.
- reference: PMID:38276922
supports: SUPPORT
snippet: New data in Crohn's disease supports the use of enteral liquid nutrition to help induce remission and correct malnutrition in patients heading for surgery.
explanation: This article supports the use of enteral nutrition as an effective therapy to induce remission and manage malnutrition in Crohn's disease.
- reference: PMID:36558412
supports: SUPPORT
snippet: Both under-and over-nutrition are prevalent in patients with Crohn's Disease (CD).
explanation: The study highlights the importance of dietary modifications to manage nutritional status in Crohn's disease patients.
- reference: PMID:35595414
supports: SUPPORT
snippet: The primary agents used in the treatment of Crohn's disease are aminosalicylates, corticosteroids, immunomodulators, and biologics. Each agent has different roles in the induction and maintenance of remission of disease.
explanation: While this primarily focuses on pharmacologic therapy, it does acknowledge the role of different agents in maintaining remission.
- reference: PMID:22410431
supports: SUPPORT
snippet: Although an elemental diet might lead to disease remission, reintroducing real foods and sustainable diets in patients with Crohn's disease is currently difficult, and would benefit from the sensitivity and rapid feedback provided by the field of nutrigenomics.
explanation: This reference suggests that dietary modifications can lead to remission and maintenance of Crohn's disease, validating the role of nutritional therapy.
treatment_term:
preferred_term: dietary intervention
term:
id: MAXO:0000088
label: dietary intervention
- name: Surgery
description: Removal of affected bowel segments, typically reserved for complications like strictures or fistulas.
evidence:
- reference: PMID:21901520
supports: SUPPORT
snippet: The indications for surgery include the failure of medical management, especially the persistence or worsening of symptoms in spite of proper treatment and complications of the disease process. These complications include intestinal obstruction, intestinal perforation with fistula formation or abscess, free perforation, gastrointestinal bleeding, urologic complications, cancer, and perianal disease.
explanation: The excerpt indicates that surgery is reserved for complications such as strictures or fistulas among others, thus supporting the statement.
- reference: PMID:32279173
supports: SUPPORT
snippet: Therefore, current therapy of fibrotic strictures relies mainly on endoscopic and surgical procedures.
explanation: The statement mentions surgery for complications like strictures, which is supported by the snippet indicating that fibrotic strictures rely on surgical procedures for treatment.
- reference: PMID:21975159
supports: SUPPORT
snippet: Intestinal resection is almost always needed for the closure of symptomatic non-perianal fistulas.
explanation: The statement links surgery to the complication of fistulas, which is supported by the snippet explaining the need for intestinal resection to manage symptomatic non-perianal fistulas.
- reference: PMID:29462390
supports: SUPPORT
snippet: When isolated to the colon, and patients become medically refractory, there are several surgical options - segmental resection, subtotal colectomy with ileorectal anastomosis, or a total proctocolectomy and end ileostomy. Unfortunately, surgery does not cure CD, and, regardless of the extent of bowel removed, recurrence may be seen in the small bowel.
explanation: The snippet supports the statement by discussing various surgical options for patients who are medically refractory, involving the removal of affected bowel segments.
- reference: PMID:36926950
supports: SUPPORT
snippet: A partial resection of 3rd and 4th portion of the duodenum and the first loop of jejunum was performed, with duodenojejunal anastomosis.
explanation: The provided case demonstrates a scenario where surgery was performed due to refractory disease and complications, supporting the statement.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
- name: Anti-IL-23 Biologics
description: Biologics targeting IL-23 (e.g., ustekinumab, risankizumab) for moderate to severe Crohn's disease refractory to anti-TNF therapy.
notes: Reflects the central role of the IL-23/Th17 axis in CD pathogenesis.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
- name: TL1A Inhibitors
description: Emerging precision therapy targeting TL1A-DR3 signaling for fistulizing and fibrostenotic disease.
notes: Under clinical investigation; addresses TNF-independent inflammatory pathways in perianal disease.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
- name: JAK Inhibitors
description: Small molecule inhibitors targeting JAK-STAT pathway for moderate to severe disease.
notes: Addresses interferon-driven inflammation and may benefit refractory cases.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
review_notes: Crohn disease is a type of inflammatory bowel disease that can affect any part of the GI tract but most commonly the terminal ileum and colon. Extraintestinal manifestations involving the joints, skin and eyes occur in a subset of patients. The disease is characterized by periods of remission interspersed with flares.
disease_term:
preferred_term: Crohn disease
term:
id: MONDO:0005011
label: Crohn disease
computational_models:
- name: AGORA2 Gut Microbiome Metabolic Models
description: >
Collection of 7,302 strain-resolved genome-scale metabolic reconstructions of human
gut microorganisms. Enables modeling of dysbiosis-associated metabolic shifts in CD,
including depletion of butyrate-producing Firmicutes (F. prausnitzii, Roseburia) and
expansion of Enterobacteriaceae. Supports integration with host intestinal epithelial
cell models.
model_type: GENOME_SCALE_METABOLIC
repository_url: https://www.vmh.life/
publication: PMID:36543475
notes: Nature Biotechnology 2022 - includes strain-level resolution for studying CD-associated dysbiosis patterns
- name: MICOM Community Metabolic Model
description: >
Metagenome-scale modeling framework for simulating metabolic interactions in the
gut microbiota. Integrates dietary constraints and taxon abundances from metagenomic
data to predict SCFA production deficits, cross-feeding network disruption, and
pathobiont metabolic niches characteristic of CD dysbiosis.
model_type: GENOME_SCALE_METABOLIC
model_software: COBRApy
publication: PMID:31964767
findings:
- statement: Community-level SCFA production is heterogeneous and highly individual-specific
evidence:
- reference: PMID:31964767
supports: SUPPORT
snippet: "the community-level production of short-chain fatty acids (SCFAs) was heterogeneous and highly individual specific"
explanation: MICOM reveals personalized SCFA flux profiles relevant to understanding IBD heterogeneity.
- statement: Model output reveals complex cross-feeding interactions that would be difficult to measure in vivo
evidence:
- reference: PMID:31964767
supports: SUPPORT
snippet: "Model output revealed complex cross-feeding interactions that would be difficult to measure in vivo"
explanation: Enables mechanistic understanding of metabolic networks disrupted in CD dysbiosis.
notes: mSystems 2020 - enables personalized microbiome metabolic modeling; applied to IBD cohorts
- name: Host-Microbiome Multi-Objective Optimization Model
description: >
Integrated metabolic model combining human intestinal epithelial cell (IEC) metabolism
with gut microbiome community models. Uses multi-objective optimization to predict
competition, mutualism, and neutralism between host and microbial metabolism. Models
SCFA exchange, amino acid cross-feeding, and metabolic interactions disrupted in CD.
model_type: GENOME_SCALE_METABOLIC
publication: PMID:38729159
notes: iScience 2024 - framework for quantifying host-microbiome metabolic crosstalk
classifications:
harrisons_chapter:
- classification_value: digestive system disorder
- classification_value: inflammatory bowel disease
- classification_value: autoimmune disease